BR112016002219A2 - estabilização de polipeptídeos contendo fc - Google Patents

estabilização de polipeptídeos contendo fc

Info

Publication number
BR112016002219A2
BR112016002219A2 BR112016002219A BR112016002219A BR112016002219A2 BR 112016002219 A2 BR112016002219 A2 BR 112016002219A2 BR 112016002219 A BR112016002219 A BR 112016002219A BR 112016002219 A BR112016002219 A BR 112016002219A BR 112016002219 A2 BR112016002219 A2 BR 112016002219A2
Authority
BR
Brazil
Prior art keywords
polypeptides
stabilization
containing polypeptides
region
sulfhydryl
Prior art date
Application number
BR112016002219A
Other languages
English (en)
Inventor
W Jacobsen Frederick
Kannan Gunasekaran
Lavallee Jennifer
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112016002219A2 publication Critical patent/BR112016002219A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

resumo estabilização de polipeptídeos contendo fc esta divulgação fornece polipeptídeos que compreendem uma região fc de anticorpo tendo uma deleção de um ou mais resíduos de cisteína na região de dobradiça e substituição por um resíduo contendo sulfidrila de um ou mais aminoácidos da interface ch3. além disso, são fornecidas proteínas de fusão a fc e anticorpos contendo os referidos polipeptídeos, ácidos nucleicos e vetores que codificam os referidos polipeptídeos, juntamente com células hospedeiras e métodos de produção dos referidos polipeptídeos.
BR112016002219A 2013-07-31 2014-07-30 estabilização de polipeptídeos contendo fc BR112016002219A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Publications (1)

Publication Number Publication Date
BR112016002219A2 true BR112016002219A2 (pt) 2017-09-12

Family

ID=52432568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002219A BR112016002219A2 (pt) 2013-07-31 2014-07-30 estabilização de polipeptídeos contendo fc

Country Status (15)

Country Link
US (2) US20160193295A1 (pt)
EP (1) EP3027647A4 (pt)
JP (2) JP2016526909A (pt)
KR (2) KR20230141929A (pt)
CN (1) CN105658664A (pt)
AU (3) AU2014296215A1 (pt)
BR (1) BR112016002219A2 (pt)
CA (1) CA2919076C (pt)
CL (1) CL2016000232A1 (pt)
EA (1) EA035319B1 (pt)
HK (1) HK1224203A1 (pt)
IL (1) IL243690B (pt)
MX (2) MX2016001165A (pt)
SG (1) SG11201600734YA (pt)
WO (1) WO2015017548A2 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MD20170020A2 (ro) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
CN115043945A (zh) * 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
JP6621478B2 (ja) 2014-12-19 2019-12-18 アルカーメス，インコーポレイテッド 一本鎖Ｆｃ融合タンパク質
CN108350048B (zh) 2015-08-07 2024-02-09 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
WO2017205014A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
WO2018005226A2 (en) * 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
DK3558339T3 (da) * 2016-12-22 2024-02-26 Cue Biopharma Inc T-celle-modulerende multimere polypeptider og fremgangsmåder til anvendelse deraf
US20190367611A1 (en) * 2017-02-01 2019-12-05 CentryMed Pharmaceutical Inc. Monomeric human igg1 fc and bispecific antibodies
TWI832818B (zh) * 2017-07-07 2024-02-21 南韓商韓美藥品股份有限公司 新穎的治療性酵素融合蛋白及其用途
MX2020001707A (es) * 2017-08-15 2020-03-20 Kindred Biosciences Inc Variantes igg fc para uso veterinario.
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
NZ765453A (en) * 2017-12-22 2024-03-22 Hanmi Pharmaceutical Co Ltd Therapeutic enzyme fusion protein having novel structure and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
UY38326A (es) 2018-08-03 2020-01-31 Amgen Inc Constructos de anticuerpos para cldn18.2 y cd3
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
US20220144916A1 (en) * 2019-02-12 2022-05-12 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
MX2021015045A (es) 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
EP4093771A1 (en) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
WO2022032660A1 (zh) * 2020-08-14 2022-02-17 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
AU2021368272A1 (en) * 2020-11-02 2023-06-08 Attralus, Inc. Sap fc fusion proteins and methods of use
MX2023005343A (es) 2020-11-06 2023-05-22 Amgen Res Munich Gmbh Construcciones polipeptidicas que se unen selectivamente a cldn6 y cd3.
WO2022120286A1 (en) * 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CA3226178A1 (en) * 2021-08-24 2023-03-02 Jiangyu YAN Gdf15 fusion proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
IL132560A0 (en) * 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
MX2007002856A (es) * 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
EP1973576B1 (en) * 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP2504360B1 (en) * 2009-11-23 2018-08-15 Amgen Inc. Monomeric antibody fc
RS55843B1 (sr) 2010-12-06 2017-08-31 Seattle Genetics Inc Humanizovana antitela za liv-1 i upotreba istih u lečenju kancera

Also Published As

Publication number Publication date
KR20230141929A (ko) 2023-10-10
CA2919076A1 (en) 2015-02-05
KR20160034404A (ko) 2016-03-29
IL243690B (en) 2022-09-01
MX2022008013A (es) 2022-07-27
EA035319B1 (ru) 2020-05-27
HK1224203A1 (zh) 2017-08-18
AU2022201204A1 (en) 2022-03-17
CN105658664A (zh) 2016-06-08
SG11201600734YA (en) 2016-02-26
JP2021019598A (ja) 2021-02-18
WO2015017548A2 (en) 2015-02-05
JP7344858B2 (ja) 2023-09-14
EA201690299A1 (ru) 2016-11-30
AU2014296215A1 (en) 2016-02-11
AU2020200329A1 (en) 2020-02-06
CL2016000232A1 (es) 2016-09-02
CA2919076C (en) 2024-01-30
IL243690A0 (en) 2016-04-21
US20190192628A1 (en) 2019-06-27
WO2015017548A3 (en) 2015-11-05
US20160193295A1 (en) 2016-07-07
EP3027647A4 (en) 2017-01-04
EP3027647A2 (en) 2016-06-08
JP2016526909A (ja) 2016-09-08
MX2016001165A (es) 2016-06-29

Similar Documents

Publication Publication Date Title
BR112016002219A2 (pt) estabilização de polipeptídeos contendo fc
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112018073628A2 (pt) anticorpos antimiostatina e métodos de utilização
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
BR112017006736A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
EA201691111A1 (ru) Химерные белки фактора viii и их применение
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
BR112017019191A2 (pt) métodos para reduzir níveis de soro de agentes que contêm fc utilizando antagonistas de fcrn
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
BR112017006112A2 (pt) formulação de proteína de fusão recombinante
BR112018071107A2 (pt) composições e métodos para a detecção de proteínas da célula hospedeira
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112015017981A2 (pt) anticorpo humano específico para metapneumovírus humano, ou fragmento de ligação de antígeno do mesmo, seu uso e composição farmacêutica o compreendendo, bem como ácido nucleico isolado, vetor de expressão recombinante e célula hospedeira

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]